The Tumor Models Conference Series is dedicated to exploring the latest advances in the application of preclinical models to enhance the translation of cancer therapies from bench to patient.
Merging its unique strategic focus and scientific quality of presentations, the event facilitates an environment of knowledge sharing and debate to actively assess how the industry is overcoming challenges in drug development through the use of in vitro & in vivo models.
Designed with input from thought leaders from over 40 organizations this represents your opportunity to benchmark your progress and enhance the translational confidence of your preclinical approaches.
Key sessions not to miss:
- Juno Therapeutics are pioneering next-generation immunotherapies through the development of state-of-the-art in vitro, rodent and non-human primate systems
- Dicerna Pharmaceuticals exploring the combination paradigm through the development of rationally designed RNAi containing drug combinations
- Seattle Genetics and Bellicium Pharmaceutical leveraging innovations in the ability to mimic TME biology & determine its fundamental role in therapeutic efficacy and PK
- Five Prime Therapeutics detailing their efforts of utilizing advanced profiling of murine tumor models enhance confidence in immuno-therapeutic
Bringing together a multidisciplinary mix of participants, from academia, industry and model providers, this is your opportunity to join 150 attendees from 80 organizations to define the future of cancer drug development.